Navidea Biopharmaceuticals (NAVB) Raised at JMP Securities

Navidea Biopharmaceuticals Inc (NAVB) is one of today’s premarket biggest movers, up more than 7% to $1.34. The move may be attributed to analysts at JMP Securities, who upgraded Navidea’s shares to a ‘Market Outperform’ and raised its price target to $5.00 from $3.00 in a research note to investors on Thursday. JMP ’s new PT suggests a potential upside of more than 309% from the company’s previous closing price.

Navidea Biopharmaceuticals closed at $1.22 at the end of Wednesday’s trading session, printing a negative 52-week change of about 57%. The stock of the $189 million market cap firm had a trading volume of 466,900 shares. NAVB, whose current negative T-12 operating margin stands at a mind-boggling (-2,125%), has a 1-year low of $1.11 and a 1-year high of $3.15. The stock’s 50-day moving average is $1.48 and its 200-day moving average is $1.72. The company has a trailing/12 price-to-sales ratio of 96.72.

The chart below shows where the equity has traded over the last 52 weeks, with the 50-day and 200-day MAs included.

Navidea Biopharmaceuticals, Inc., is a developer and commercializer of precision diagnostics and radiopharmaceutical agents. The company was founded in 1983 and is headquartered in Dublin, Ohio.

Disclosure: No Position

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.